Samyag

Corporate Actions

Back

Jubilant Pharmova arm gets tentative nod for Pantoprazole oral suspension

26-Jun-26 12:03 Hrs IST

Jubilant Generics is a subsidiary of Jubilant Pharma, which is a wholly owned subsidiary of the company.

The said drug is primarily used to treat gastroesophageal reflux disease (GERD), heal acid-related damage to the esophagus.

The aforesaid tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026. Final approval is anticipated upon such patent expiry.

The said approval follows successful completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the solid dosage manufacturing facility located at Roorkee.

Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The company's consolidated net profit declined 22.27% to Rs 119.40 crore, while net sales rose 18.60% to Rs 2,272.20 crore in Q4 FY26 compared with Q4 FY25.

The scrip shed 0.84% to settle at Rs 964.05 on Thursday, 25th June 2026. The stock market is shut today on account of Muharram.

Powered by Capital Market - Live News

Attention Investors:

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. || KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. || No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.